|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1993-3-1
|
|
pubmed:abstractText |
Seventy-three patients with stage C and D prostatic carcinoma were treated with hormonotherapy. During a mean follow-up of 27 +/- 17.8 months, 30 tumour-related deaths were registered. The patients in the G3 subset suffered a 35.7% early death rate versus a 10.1% rate of G1-2 ones. This difference is significant (p = 0.0102). Nevertheless the Authors' opinion is that G3 patients should not be given a more aggressive treatment initially apart from the case of a controlled trial.
|
|
pubmed:language |
ita
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0393-2249
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
44
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
205-8
|
|
pubmed:dateRevised |
2008-6-23
|
|
pubmed:meshHeading |
pubmed-meshheading:1492272-Aged,
pubmed-meshheading:1492272-Aged, 80 and over,
pubmed-meshheading:1492272-Carcinoma,
pubmed-meshheading:1492272-Combined Modality Therapy,
pubmed-meshheading:1492272-Flutamide,
pubmed-meshheading:1492272-Goserelin,
pubmed-meshheading:1492272-Humans,
pubmed-meshheading:1492272-Life Tables,
pubmed-meshheading:1492272-Male,
pubmed-meshheading:1492272-Middle Aged,
pubmed-meshheading:1492272-Neoplasm Staging,
pubmed-meshheading:1492272-Orchiectomy,
pubmed-meshheading:1492272-Prostatic Neoplasms,
pubmed-meshheading:1492272-Survival Analysis,
pubmed-meshheading:1492272-Survival Rate
|
|
pubmed:articleTitle |
[Advanced carcinoma of the prostate (stages C and D). Mortality within 12 months of the initiation of hormonal therapy].
|
|
pubmed:affiliation |
Divisione di Urologia, USSL n. 76, Casale Monferrato, Alessandria.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
English Abstract
|
